Cytosorbents Corp Dossier
|
SectorHealth Care IndustryHealth Care Equipment Beta (adjusted)1.22 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $4.18Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $13.2M Enterprise Value $26M Shares Outstanding 3.2M diluted Next Earnings Date12 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Cytosorbents Corp (CTSO) is a medical device leader specializing in blood purification therapies, primarily through its flagship CytoSorb device. While international sales outside Germany continue to grow, the company faces significant near-term headwinds. Its primary U.S. growth catalyst, the DrugSorb-ATR antithrombotic removal system, has experienced regulatory delays following the FDA's De Novo application denial. The company is currently gathering additional mechanistic data to support a new submission in late 2026 or early 2027. Financially, Cytosorbents is focused on aggressive cost-cutting and workforce reductions to achieve operating cash flow breakeven in the second half of 2026. However, with a tight cash runway and Nasdaq listing non-compliance requiring a reverse stock split, the stock remains a high-risk, speculative hold until regulatory clarity in the U.S. is achieved. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$0.75 Mean target$2.38 High · most bullish analyst$4.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The FDA demands additional expensive clinical trials rather than just mechanistic data, pushing the DrugSorb-ATR U.S. commercialization timeline past 2028. German sales continue to decline, and international growth slows. The company fails to achieve cash flow breakeven in H2 2026, forcing highly dilutive equity raises or covenant defaults on its debt facility. Base CaseCentral scenario The company successfully aligns with the FDA on the required mechanistic data and submits a new De Novo application for DrugSorb-ATR by early 2027. International sales continue to grow modestly, and cost-reduction initiatives successfully drive the company to operating cash flow breakeven in late 2026. Shareholders approve the reverse stock split, resolving the Nasdaq listing compliance issue. Bull CaseUpside scenario Successful FDA De Novo approval of DrugSorb-ATR in late 2026 or early 2027, unlocking a $500M-$1B U.S. addressable market and driving rapid revenue acceleration. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |